A5067332117- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Esophageal Cancer Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer therapeutics and mechanisms
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
University of Southern California
2016-2025
USC Norris Comprehensive Cancer Center
2016-2025
Quaid-i-Azam University
2025
Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir
2024
Cork University Hospital
2020
Footscray Hospital
2018
Western Health
2014-2018
Barwon Health
2018
Geelong Hospital
2018
Fox Chase Cancer Center
2014
Purpose Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti–epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with metastatic colorectal cancer (CRC). Recent studies demonstrate antibody-dependent cell-mediated cytotoxicity (ADCC) is one the modes action for rituximab and trastuzumab. Fragment c (Fc) portion IgG1 mAb to induce ADCC. gamma receptors (FcγR) play an important role initiating Studies have that two IgG FcγR polymorphisms...
A 6 bp deletion polymorphism in the thymidylate synthase (TS) gene was investigated order to determine its function.A luciferase system used investigate function of bp/1494 vitro. group 43 patients with colorectal carcinoma were evaluated for and intratumoral TS mRNA levels vivo.The 3'UTR containing +6 resulted an approximate 35% decrease activity levels, while TS-3'UTR bearing -6 70% levels. The construct also had a higher rate message degradation compared construct. Individuals homozygous...
Purpose To investigate whether mRNA expression levels of cyclin D1 (CCND1), cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), interleukin 8 (IL-8), and vascular endothelial (VEGF), all members the EGFR signaling pathway, are associated with clinical outcome in patients EGFR-expressing metastatic colorectal cancer (CRC) treated cetuximab. Patients Methods Thirty-nine CRC, refractory to both irinotecan oxaliplatin, were enrolled on IMCL-0144 single-agent The intratumoral...
BackgroundLapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human 2 (HER2/ErbB2), which are reported as overexpressed in 15%–45% gastric cancers, making them potential targets.Patients methodsThe primary objective this study was to assess response rate. Secondary objectives included overall survival (OS), toxicity, the relationship EGFR, ErbB2, markers angiogenesis with clinical outcome. Lapatinib administered chemonaive metastatic cancer...
Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with poor prognosis in advanced stages. On the basis evidence dysregulation epidermal growth factor receptor, vascular endothelial mitogen-activated protein kinase pathways biliary cancers, we performed phase 2 trial sorafenib erlotinib patients cancers. Eligible were previously untreated setting adequate hepatic bone marrow function. Sorafenib administered continuously at 400 mg BID 100 daily, respectively....
Abstract Purpose: GEP-NENs are rare malignancies with increasing incidence. Their molecular characteristics still undefined. We explored the underlying biology of and differences between gastrointestinal (GI) pancreatic (PNEN), high-grade (HG), low-grade (LG) tumors. Experimental Design: were analyzed using next-generation sequencing (NGS; MiSeq on 47 genes, NextSeq 592 genes), IHC, in situ hybridization. Tumor mutational burden (TMB) was calculated basis somatic nonsynonymous missense...
347 Background: Zanidatamab (zani) is an anti-HER2 bispecific antibody against ECD4 and ECD2 with demonstrated activity tolerability in a range of HER2-expressing cancers. This Phase (Ph) 2 study (NCT03929666) evaluates zani combination chemotherapy (chemo) as first-line treatment for patients (pts) advanced mGEA. Methods: Eligible pts this ongoing, open-label had not received any prior systemic therapy Pts + physician’s choice multi-agent chemo (mFOLFOX6, CAPOX, or FP). Antidiarrheal...
The study aimed to investigate whether polymorphisms in genes of the EGFR signaling pathway are associated with clinical outcome advanced colorectal cancer (CRC) patients treated single-agent Cetuximab. Polymorphisms interest include: cyclin D1 (CCND1) A870G, cyclooxygenase 2 (Cox-2) G-765C, epidermal growth factor (EGF) A61G, receptor (EGFR) codon R497 K, CA dinucleotide repeat intron 1, interleukin (IL)-8 T-251A and vascular endothelial (VEGF) C936 T gene polymorphisms. Thirty-nine...
BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to affect its natural history. We tested the hypothesis that simulataneous targeting of epidermal growth factor receptor (EGFR) and insulin‐like receptor–1 (IGF‐1R) pathways would significantly improve progression‐free survival (PFS) by abrogating reciprocal signaling promote drug resistance METHODS This was phase Ib/II study testing cixutumumab, combined with erlotinib gemcitabine (G) patients untreated...
BACKGROUND The AKT inhibitor MK‐2206 at a dose of 60 mg every other day was evaluated in gastric/gastroesophageal junction cancers. METHODS Patients who had progressed after first‐line treatment were eligible. Pertinent eligibility criteria included adequate organ function, fasting serum glucose level ≤ 150 mg/dL, and less than grade 2 malabsorption or chronic diarrhea. given orally (60 evaluable patients required). primary endpoint overall survival, median survival 6.5 months (power, 89%;...
15 Background: Immune check point inhibitors (ICI) are ineffective in MSSCRC. Combination of ICI with targeted agents has the potential to alter tumor microenvironment and render these tumors vulnerable ICI. We report results multicenter study rego pembro a diverse patient population advanced Methods: This was an investigator-initiated enrolled patients (pts) who had failed/were intolerant chemotherapy at 3 sites. A 3+3 design used for phase I evaluate escalating doses (80,120,160, days...
TPS430 Background: Anti-VEGFR2 antibody (ramucirumab) has efficacy in gastric cancer (GC), both as monotherapy & combination with paclitaxel based on the REGARD RAINBOW trials that led to its FDA approvals 2 nd line setting. Preclinical data demonstrate significant tumor immune microenvironment modulatory effects from antiangiogenic agents, supporting clinical study of dual VEGFR checkpoint blockade. This resulted at least 7 FDA-approved combinations anti-VEGF/VEGFR anti-PD-1/PD-L1...
Abstract DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared regorafenib or TAS‐102 pts with advanced mCRC refractory irinotecan. Patients were randomized 2:1 (Arm A) vs standard care B) on 28‐day cycle. Between January 15, 2016 October 24, 2018, 104 at four international sites, 96 undergoing treatment, 62 Arm A 34 B. Median overall survival was...
Abstract Evidence is accumulating supporting gender-related differences in the development of colonic carcinomas. Sex steroid hormone receptors are expressed colon and interact with epidermal growth factor receptor (EGFR), a gene widely tissue. Increased EGFR expression linked poor prognosis cancer. Within there two functional polymorphisms interest: polymorphism located at codon 497 (HER-1 R497K) dinucleotide (CA)n repeat within intron 1. These germ-line were analyzed genomic DNA from 318...
Purpose Pathologic complete response (pCR) after neoadjuvant therapy for locally advanced esophageal adenocarcinoma is associated with improved survival. The Southwest Oncology Group designed a trimodality, phase II, single-arm trial objectives of achieving pCR rate 40% prospective exploratory analyses intratumoral molecular markers postulated to affect and Patients Methods clinically staged II or III received oxaliplatin 85 mg/m 2 on days 1, 15, 29; protracted-infusion fluorouracil (PI-FU)...
4027 Background: DKN-01 is an anti-DKK1 mAb which has demonstrated anti-tumor activity in patients with advanced GEA low tumor PD-L1 expression, a subset very limited therapeutic options. immunomodulatory activity, stimulates pro-inflammatory microenvironment, and upregulates levels. Here we present 2-year survival data for 1L who received combination treatment DKN-01, the Fc-optimized anti-PD-1 tislelizumab, CAPOX chemotherapy. The ORR was previously reported (68% ITT 79% PD-L1-low...
Summary. Venous thromboembolism (VTE) is a well‐recognized complication of autoimmune haemolytic anaemia (AIHA), and major cause morbidity mortality in this disorder. However, the incidence, pathogenesis risk‐factors for VTE AIHA remain poorly defined. Lupus anticoagulants (LA) anticardiolipin (ACA) antibodies are autoantibodies directed against epitopes on prothrombin or β2 glycoprotein I (β2‐GPI). Both LA ACA (together called antiphospholipid antibodies, APLA) associated with VTE. We have...
Molecular markers predicting the efficacy of CPT-11 based chemotherapies in patients with colorectal cancer (CRC) are unknown. Therefore, we investigated whether mRNA levels drug targets (Topoisomerase I, TS), enzymes involved 5-FU metabolism (DPD), angiogenesis (EGFR, IL-8, VEGF) and DNA-repair/drug detoxification (ERCC1, GST-P1) associated clinical outcome CRC treated first-line chemotherapy. Thirty three metastatic were included study. Intratumoral gene expression assessed from...